Hemophilia affects roughly 3.75 out of every 100,000 people worldwide, which works out to about 0.004% of the global population. That makes it a genuinely rare condition. In the United States, an estimated 30,000 to 33,000 males are currently living with hemophilia, and the condition occurs in approximately 1 out of every 5,000 male births.
Global Prevalence Is Rising
While hemophilia remains rare by any measure, the number of diagnosed cases is growing. Global prevalence rose from 2.75 per 100,000 people in 2014 to 3.75 per 100,000 in 2023. Projections suggest it could reach 4.87 per 100,000 by 2030. This increase likely reflects better diagnosis and reporting in countries that previously undercounted cases, along with longer survival thanks to modern treatment. More people living longer with hemophilia means more people alive with the condition at any given time.
That survival improvement has been dramatic. The median age at death for males with hemophilia rose from 54.5 years in the 1999 to 2009 period to 65.5 years in the 2010 to 2020 period. Just a few decades ago, severe hemophilia often meant a significantly shortened life. Today, with access to treatment, many people with hemophilia live into their 60s and beyond.
Hemophilia A vs. Hemophilia B
There are two main types. Hemophilia A, caused by a deficiency in one clotting protein, is the more common form and accounts for roughly 80% of all cases. Hemophilia B, involving a different clotting protein, makes up most of the remaining 20%. Both are inherited through the X chromosome, which is why the condition overwhelmingly affects males.
A third, even rarer form called hemophilia C affects an estimated 1 in 100,000 people. Unlike types A and B, hemophilia C is not linked to the X chromosome and can affect males and females equally. All forms of hemophilia, including several other rare clotting factor deficiencies, each affect fewer than 200,000 people in the U.S., meeting the formal definition of a rare disease.
Why It Mostly Affects Males
Hemophilia A and B are X-linked conditions. Males have one X chromosome and one Y, so a single faulty gene on the X chromosome is enough to cause the disorder. Females have two X chromosomes, meaning they would need to inherit two defective copies to have full hemophilia, which is extremely rare.
That said, women who carry one copy of the gene are not always symptom-free. Carriers with clotting factor levels below 60% of normal can experience increased bleeding. Research comparing 135 carriers to non-carriers found that the carrier group had significantly higher rates of bruising, prolonged bleeding from small wounds, and extended bleeding after dental extractions, surgery, and childbirth. When clotting factor levels dropped below 20% of normal, carriers faced a 50% risk of excessive bleeding after surgical procedures. These symptomatic carriers are sometimes called “manifesting carriers,” and their bleeding tendencies track closely with how low their clotting factor levels actually are.
Severity Varies Widely
Not everyone with hemophilia experiences it the same way. The condition is classified as mild, moderate, or severe based on how much functional clotting factor a person’s blood contains. People with severe hemophilia may bleed spontaneously into joints and muscles without any obvious injury. Those with mild hemophilia might only notice unusual bleeding after surgery or a significant trauma, and some go undiagnosed for years.
The severity level shapes nearly every aspect of daily life, from how often treatment is needed to what physical activities are safe. Someone with mild hemophilia may rarely think about their condition between medical checkups, while someone with a severe form often needs regular preventive infusions to avoid joint damage from repeated internal bleeding.
Racial Disparities in Outcomes
Hemophilia occurs at similar rates across racial and ethnic groups, but outcomes are not equal. Black males with hemophilia in the U.S. die earlier (median age 56) compared to white males (median age 68), a gap of 12 years. Because the condition occurs at roughly the same rate regardless of race, this difference points to disparities in access to care, treatment quality, or both rather than any biological difference in disease severity.